Northwest Biotherapeutics, Inc. (NWBO) Financials
NWBO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 75.9 million | 110.7 million |
| March 31, 2026 | 80.1 million | 118.1 million |
| Dec. 31, 2025 | 81.3 million | 128.9 million |
| Sept. 30, 2025 | 30.6 million | 125.9 million |
NWBO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -7.0 million | 181000 |
| March 31, 2026 | -12.6 million | 288000 |
| Dec. 31, 2025 | -15.2 million | 185000 |
| Sept. 30, 2025 | -13.5 million | 273000 |
NWBO Net Income
No data available :(
NWBO Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 595000 | 22.7 million | - |
| March 31, 2026 | 1.8 million | 16.2 million | 4.6 million |
| Dec. 31, 2025 | 3.0 million | 17.9 million | 4.8 million |
| Sept. 30, 2025 | 4.6 million | 31.8 million | 4.8 million |
NWBO Shares Outstanding
NWBO Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 129000 | 5.7 million | 6.7 million | - |
| March 31, 2026 | 129000 | 4.9 million | 6.5 million | - |
| Dec. 31, 2025 | 397000 | 5.6 million | 8.6 million | - |
| Sept. 30, 2025 | 397000 | 7.5 million | 7.1 million | - |
NWBO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 807000 | - |
| March 31, 2026 | 494000 | 847000 |
| Dec. 31, 2025 | 672000 | 801000 |
| Sept. 30, 2025 | 200000 | 521000 |
NWBO
Price: $0.19
52 week price:
Payout Ratio Range:
Earnings Per Share: -0.06 USD
P/E Ratio: -3.73
Exchange: OQB
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.3 million
Ebitda: -69.1 millionMarket Capitalization: 261.3 million